Bernstein CN, Loftus EV Jr., Ng SC et al. Hospitalisations and surgery in Crohn’s disease. Gut 2012;61:622–629.
Peyrin-Biroulet L, Loftus EV Jr., Colombel JF et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol 2010;105:289–297.
Peyrin-Biroulet L, Loftus EV Jr., Colombel JF et al. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn’s disease in population-based cohorts. Inflamm Bowel Dis 2011;17:471–478.
Magro F, Rodrigues A, Vieira AI et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis 2012;18:573–583.
Torres J, Billioud V, Sachar DB et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012;18:1356–1363.
Frolkis AD, Dykeman J, Negron ME et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013;145:996–1006.
Jess T, Simonsen J, Jorgensen KT et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012;143:375–381.
Vester-Andersen MK, Prosberg MV, Jess T et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol 2014;109:705–714.
Pariente B, Cosnes J, Danese S et al. Development of the Crohn’s disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011;17:1415–1422.
Peyrin-Biroulet L, Cieza A, Sandborn WJ et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61:241–247.
Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2014;12:929–934.
Sandborn WJ, Hanauer S, Van Assche G et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014;8:927–935.
Mosli MH, Feagan BG, Sandborn WJ et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis 2014;20:564–575.
Jìrgens M, Mahachie John JM, Cleynen I et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2011;9:421–427.
Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817–1826.
D'Haens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218–2224.
Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1246–1256.
Pincus T, Gibofsky A, Weinblatt ME. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum 2002;46:851–854.
Bouguen G, Levesque BG, Feagan BG et al. Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin Gastroenterol Hepatol 2013, S1542–S3565.
Rachmani R, Slavacheski I, Berla M et al. Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study. J Am Soc Nephrol 2005;16:S22–S26.
Eeg-Olofsson K, Cederholm J, Nilsson PM et al. Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 2007;30:496–502.
Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829–840.
Pearson TA. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. Am J Cardiol 2004;94:4f–8f.
Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207.
Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem 2009;55:219–228.
Pariente B, Cosnes J, Danese S et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011;17:1415–1422.
Best WR, Becktel JM, Singleton JW et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70:439–444.
Thia KT, Sandborn WJ, Lewis JD et al. Defining the optimal response criteria for the Crohn’s disease activity index for induction studies in patients with mildly to moderately active Crohn’s disease. Am J Gastroenterol 2008;103:3123–3131.
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980;1:514.
Vermeire S, Schreiber S, Sandborn WJ et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol 2010;8:357–363.
Hyams JS, Ferry GD, Mandel FS et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439–447.
Turner D, Mack D, Leleiko N et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010;138:2282–2291.
Peyrin-Biroulet L, Reinisch W, Colombel JF et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 2014;63:88–95.
Jones J, Loftus EV Jr., Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2008;6:1218–1224.
Modigliani R, Mary JY, Simon JF et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811–818.
Levesque BG, Sandborn WJ, Ruel J et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 2015;148:37–51.
Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–1395.
Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–1549.
Panaccione R, Colombel JF, Sandborn WJ et al. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther 2013;38:1236–1247.
Daperno M, D'Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505–512.
Khanna R, Zou G, D'Haens G et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn’s disease. Gut.
Sipponen T, Savilahti E, Karkkainen P et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis 2008;14:1392–1398.
Sipponen T, Savilahti E, Kolho KL et al. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40–46.
Smith JP, Bingaman SI, Ruggiero F et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci 2011;56:2088–2097.
Ferrante M, Colombel JF, Sandborn WJ et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013;145:978–986.
Ferrante M, de Hertogh G, Hlavaty T et al. The value of myenteric plexitis to predict early postoperative Crohn’s disease recurrence. Gastroenterology 2006;130:1595–1606.
Gecse K, Lowenberg M, Bossuyt P et al. Sa1198 Agreement among experts in the endoscopic evaluation of postoperative recurrence in Crohn’s disease using the Rutgeerts score. Gastroenterology 2014;146:S-227.
Reinisch W, Angelberger S, Petritsch W et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010;59:752–759.
Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010;138:463–468.
Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–1201.
De Cruz P, Kamm MA, Prideaux L et al. Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis 2013;19:429–444.
D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660–667.
Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619–1635.
Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006;63:433–442.
Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 2009;15:1295–1301.
Bryant RV, Winer S, Travis SP et al. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014;8:1582–1597.
Goldman H, Antonioli DA. Mucosal biopsy of the rectum, colon, and distal ileum. Hum Pathol 1982;13:981–1012.
Langner C, Magro F, Driessen A et al. The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch 2014;464:511–527.
Magro F, Langner C, Driessen A et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013;7:827–851.
Geboes K, Riddell R, Ost A et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404–409.
Ordás I, Rimola J, Rodriguez S et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology 2014;146:374–382.
Panés J, Bouhnik Y, Reinisch W et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 2013;7:556–585.
Panés J, Bouzas R, Chaparro M et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther 2011;34:125–145.
Siddiki HA, Fidler JL, Fletcher JG et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn’s disease. AJR Am J Roentgenol 2009;193:113–121.
Solem CA, Loftus EV Jr., Fletcher JG et al. Small-bowel imaging in Crohn’s disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008;68:255–266.
Ordas I, Rimola J, Rodriguez S et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology 2014;146:374–382.
Rimola J, Ordas I, Rodriguez S et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011;17:1759–1768.
Rimola J, Rodriguez S, Garcia-Bosch O et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut 2009;58:1113–1120.
Bosch OG, Ordâs I, Rodriguez S et al. 90 Comparison of the impact of MRI and colonoscopy on management of Crohn’s disease. Gastroenterology 2012;142:S-21–S-22.
Bruining DH, Loftus EV Jr., Ehman EC et al. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2011;9:679–683.
Bruining DH, Siddiki HA, Fletcher JG et al. Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. Inflamm Bowel Dis 2012;18:219–225.
Takenaka K, Ohtsuka K, Kitazume Y et al. Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn’s disease. Gastroenterology 2014;147:334–342.
Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323–333.
Kiss LS, Papp M, Lovasz BD et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn’s disease: a marker for patient classification? Inflamm Bowel Dis 2012;18:1647–1654.
Lamireau T, Cézard JP, Dabadie A et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn’s disease. Inflamm Bowel Dis 2004;10:745–750.
Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999;117:761–769.
Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 1997;349:521–524.
Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029–1035.
Reinisch W, Wang Y, Oddens BJ et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn’s disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012;35:568–576.
Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357:228–238.
Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005;129:807–818.
Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63–70.
Treton X, Bouhnik Y, Mary JY et al. Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80–85.
Florin TH, Paterson EW, Fowler EV et al. Clinically active Crohn’s disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006;41:306–311.
Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805–1812.
Gisbert JP, Bermejo F, Perez-Calle JL et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190–1198.
De Cruz P, Kamm MA, Hamilton AL et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015;385:1406–1417.
Khanna R, Zou G, D'Haens G et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn’s disease activity. Aliment Pharmacol Ther 2015;41:77–86.
Burisch J, Weimers P, Pedersen N et al. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease—an ECCO-EpiCom study. J Crohns Colitis 2014;8:1030–1042.
Drossman DA, Leserman J, Li ZM et al. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991;53:701–712.
Guyatt G, Mitchell A, Irvine EJ et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804–810.
Irvine EJ, Feagan B, Rochon J et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287–296.
Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571–1578.
Jenkinson C, Gray A, Doll H et al. Evaluation of index and profile measures of health status in a randomized controlled trial. Comparison of the Medical Outcomes Study 36-Item Short Form Health Survey, EuroQol, and disease specific measures. Med Care 1997;35:1109–1118.
Lönnfors S, Vermeire S, Greco M et al. IBD and health-related quality of life—Discovering the true impact. J Crohns Colitis 2014;8:1281–1286.
Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992;14:15–19.
McColl E, Han SW, Barton JR et al. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res 2004;13:805–811.
van der Have M, van der Aalst KS, Kaptein AA et al. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis 2014;8:93–106.
Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–483.
Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 2009;15:1105–1118.
Mikocka-Walus AA, Turnbull DA, Moulding NT et al. Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: a literature review. Inflamm Bowel Dis 2007;13:225–234.
Nahon S, Lahmek P, Durance C et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2086–2091.
Beck AT, Ward CH, Mendelson M et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
Lichtenstein GR, Bala M, Han C et al. Infliximab improves quality of life in patients with Crohn’s disease. Inflamm Bowel Dis 2002;8:237–243.
Loftus EV, Feagan BG, Colombel JF et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132–3141.
Loftus EV Jr., Guerin A, Yu AP et al. Increased risks of developing anxiety and depression in young patients with Crohn’s disease. Am J Gastroenterol 2011;106:1670–1677.
Minderhoud IM, Samsom M, Oldenburg B. Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 2007;13:2089–2093.
Reinisch W, Sandborn WJ, Bala M et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:1135–1140.
Zhang CK, Hewett J, Hemming J et al. The influence of depression on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1732–1739.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370.
Zung WW. The Depression Status Inventory: an adjunct to the Self-Rating Depression Scale. J Clin Psychol 1972;28:539–543.
Beck A, Bager P, Jensen PE et al. How fatigue is experienced and handled by female outpatients with inflammatory bowel disease. Gastroenterol Res Pract 2013;2013:153818.
Czuber-Dochan W, Ream E, Norton C. Review article: Description and management of fatigue in inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:505–516.
Graff LA, Clara I, Walker JR et al. Changes in fatigue over 2 years are associated with activity of inflammatory bowel disease and psychological factors. Clin Gastroenterol Hepatol 2013;11:1140–1146.
Jelsness-Jorgensen LP, Bernklev T, Henriksen M et al. Chronic fatigue is associated with increased disease-related worries and concerns in inflammatory bowel disease. World J Gastroenterol 2012;18:445–452.
Romberg-Camps MJ, Bol Y, Dagnelie PC et al. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis 2010;16:2137–2147.
Smets EM, Garssen B, Bonke B et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315–325.
Tinsley A, Macklin EA, Korzenik JR et al. Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:1328–1336.
van Langenberg DR, Gibson PR. Factors associated with physical and cognitive fatigue in patients with Crohn's disease: a cross-sectional and longitudinal study. Inflamm Bowel Dis 2014;20:115–125.
Vogelaar L, van't Spijker A, van Tilburg AJ et al. Determinants of fatigue in Crohn’s disease patients. Eur J Gastroenterol Hepatol 2013;25:246–251.
Yellen SB, Cella DF, Webster K et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63–74.
Reilly MC, Gerlier L, Brabant Y et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn’s disease. Clin Ther 2008;30:393–404.
Høivik ML, Moum B, Solberg IC et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut 2013;62:368–375.
Israeli E, Graff LA, Clara I et al. Low prevalence of disability among patients with inflammatory bowel diseases a decade after diagnosis. Clin Gastroenterol Hepatol 2014;12:1330–1337.
Mandel MD, Bálint A, Lovász BD et al. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ 2014;15:S121–S128.
van der Valk ME, Mangen MJ, Leenders M et al. Risk factors of work disability in patients with inflammatory bowel disease—a Dutch nationwide web-based survey: work disability in inflammatory bowel disease. J Crohns Colitis 2014;8:590–597.
Spiegel BM, Hays RD, Bolus R et al. Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 2014;109:1804–1814.
Colombel JF, Rutgeerts PJ, Sandborn WJ et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014;12:414–422.
Colombel JF, Reinisch W, Mantzaris GJ et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn’s disease—a SONIC post hoc analysis. Aliment Pharmacol Ther 2015;41:734–746.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–1629.
Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82–86.
Walmsley RS, Ayres RC, Pounder RE et al. A simple clinical colitis activity index. Gut 1998;43:29–32.
Turner D, Otley AR, Mack D et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423–432.
Travis SP, Schnell D, Krzeski P et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535–542.
Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710.
Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392–400.
Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–2476.
Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257–265.
Turner D, Seow CH, Greenberg GR et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1081–1088.
Lewis JD, Lichtenstein GR, Deren JJ et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008;134:688–695.
Feagan BG, Reinisch W, Rutgeerts P et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007;102:794–802.
Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250–1260.
Feagan BG, Sandborn WJ, D'Haens G et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145:149–157.
Inoue N, Takabayashi K, Takayama T et al. P215 Endoscopic remission (Mayo score 0 rather than score 1) predicts long-term clinical remission in ulcerative colitis. J Crohns Colitis 2013;7:S95.
Yokoyama K, Kobayashi K, Mukae M et al. Clinical study of the relation between mucosal healing and long-term outcomes in ulcerative colitis. Gastroenterol Res Pract 2013;2013:192794.
Travis SP, Schnell D, Krzeski P et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013;145:987–995.
Pola S, Feagan BG, Fahmy M et al. Tu1106 Observer agreement and construct validity in central endoscopic assessment of disease activity in ulcerative colitis. Gastroenterology 2013;144:S-763.
Levesque BG, Loftus EV, Panaccione R et al. P150 responsiveness of endoscopic indices in the evaluation of ulcerative colitis. J Crohns Colitis 2014;8:S124.
Samuel S, Bruining DH, Loftus EV Jr. et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2013;11:49–54.
Thia KT, Loftus EV Jr., Pardi DS et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis 2011;17:1257–1264.
Bitton A, Peppercorn MA, Antonioli DA et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13–20.
Riley SA, Mani V, Goodman MJ et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174–178.
Ordás I, Rimola J, Garcia-Bosch O et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut 2013;62:1566–1572.
Oussalah A, Laurent V, Bruot O et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut 2010;59:1056–1065.
Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83–88.
Aceituno M, Garcia-Planella E, Heredia C et al. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008;14:347–352.
Cacheux W, Seksik P, Lemann M et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008;103:637–642.
Gordon FH, Hamilton MI, Donoghue S et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002;16:699–705.
Henriksen M, Jahnsen J, Lygren I et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57:1518–1523.
Kumar S, Ghoshal UC, Aggarwal R et al. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol 2004;19:1247–1252.
Osada T, Ohkusa T, Okayasu I et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol 2008;23:S262–S267.
Solem CA, Loftus EV Jr., Tremaine WJ et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707–712.
Yoon JY, Park SJ, Hong SP et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci 2014;59:829–837.
De Vos M, Louis EJ, Jahnsen J et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013;19:2111–2117.
Molander P, af Bjorkesten CG, Mustonen H et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflamm Bowel Dis 2012;18:2011–2017.
Osterman MT, Aberra FN, Cross R et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2014;12:1887–1893.
Yamamoto T, Shiraki M, Bamba T et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis 2014;29:485–491.
Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96–109.
Sandborn WJ, Colombel JF, D'Haens G et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37:204–213.
Cohen BL, Zoega H, Shah SA et al. Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity. Aliment Pharmacol Ther 2014;39:811–822.
Sherman M, Tsynman DN, Kim A et al. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J Dig Dis 2014;15:174–179.
Ardizzone S, Maconi G, Russo A et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47–53.
Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966;11:847–857.
Annese V, Daperno M, Rutter MD et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7:982–1018.
Fengming Y, Jianbing W. Biomarkers of inflammatory bowel disease. Dis Markers 2014;2014:710915.
Peyrin-Biroulet L, Billioud V, D'Haens G et al. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol 2012;107:1770–1776.